济南几秒就完了怎么治济南治阳痿要用什么,济南治早泄的好药,济南早泄肾虚阳痿怎么治疗方法,济南包皮怎么叫过长,济南进去一会就射了怎么办,济南导致性生活时间短的主要原因,济南怎么办我阳痿

BEIJING, Jan. 29 (Xinhua) -- Chinese State Councilor Dai Bingguo and U.S. National Security Advisor Tom Donilon on Saturday both spoke highly of Chinese President Hu Jintao's state visit to the United States earlier this month.During a phone conversation, Dai and Donilon agreed that China and the United States should make joint efforts to properly implement the consensus reached by leaders on both sides and cement the achievements made during Hu's visit, which was on Jan. 18-21.They also said that the two sides should maintain the current momentum in the development of bilateral ties and devote themselves to building a cooperative partnership based on mutual respect and mutual benefit.

GENEVA, March 28 (Xinhua) -- The world is ill-prepared to respond to a severe influenza pandemic or to any similarly global, sustained, and threatening public health emergency, an independent expert-committee entrusted by World Health Organization (WHO) said at its fourth meeting here on Monday.The Review Committee, tasked to look into the experience gained in the global response to the influenza A (H1N1) pandemic in 2009, issued its preliminary report at the meeting.In the report, the Committee said, "global preparedness can be advanced through research, strengthened health-care delivery systems, economic development in low and middle-income countries and improved health status."It recommended that international society establish an extensive global public health reserve corps consisted of experts and public health professionals, which could be deployed to support countries in need, in case of future pandemics.Another suggestion was to create a contingency fund for public health emergencies to be held in trust at an institution such as the World Bank, in order to provide financial support during a declared public health emergency of international concern.The report also urged WHO member states to reach an agreement on sharing of viruses and access to vaccines, and encouraged them to run independent or cooperative influenza research program.WHO Director-General Margaret Chan said at the opening of the meeting that the report had offered "critical guidance to all ministers of health who need to make far-reaching decisions."She said the recommendations in the report would help to " improve the capacity of WHO and the international community to respond to public health emergencies" and therefore should be taken with "added urgency."In January 2010, WHO's Executive Board established a Review Committee, at Chan's proposal, to review the experience gained in response to the H1N1 pandemic, as well as the International Health Regulations and WHO's functioning in tackling the disease.The Committee is expected to prepare its final report out of the current preliminary version, and submit it to the decision- making body of WHO in May.

BEIJING, Jan. 27 (Xinhua) -- A senior Chinese official has called on the country's religious figures to make more contributions to economic and social development by innovating and improving social services.Jia Qinglin, a member of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee, made the remark at a meeting Thursday while offering lunar New Year's greetings to religious circles on behalf of the CPC Central Committee.Jia Qinglin (front, R), chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), and a member of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee, shakes hands with one of the leaders of the religious groups during an informal discussion sponsored by CPPCC in Beijing, capital of China, Jan. 27, 2011, to celebrate the upcoming Spring Festival.Jia said Chinese citizens' freedom in religious belief was fully protected, and the religious circles had provided excellent services for people from around the world during the Shanghai World Expo and Guangzhou Asian Games last year.The official asked the religious circles to pay more attention to helping grassroots religious groups and believers and improving their management.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.